A 300 IR sublingual tablet is an effective,safe treatment for house dust mite–induced allergic rhinitis: An international,double-blind,placebo-controlled,randomized phase III clinical trial

1. Download : Download high-res image (382KB)
2. Download : Download full-size image

     

Determinants of omalizumab dose–related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients

1. Download : Download high-res image (216KB)
2. Download : Download full-size image

     

Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1

1. Download : Download high-res image (298KB)
2. Download : Download full-size image

     

Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial

1. Download : Download high-res image (276KB)
2. Download : Download full-size image

     

Suppression of IgE-mediated anaphylaxis and food allergy with monovalent anti-FcεRIα mAbs

1. Download : Download high-res image (370KB)
2. Download : Download full-size image

     

Mutation in KARS: A novel mechanism for severe anaphylaxis

1. Download : Download high-res image (249KB)
2. Download : Download full-size image

     

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan

Background & aimsTreatment of hepatitis C virus (HCV) by elbasvir/grazoprevir (EBR/GZR) was found to be efficacious and well tolerated in clinical trials. This study aimed to evaluate the effectiveness and tolerability of EBR/GZR in the treatment of HCV genotype 1-infected Taiwanese patients.MethodsChronic hepatitis C patients infected with GT1b or 1a without resistance-associated substitution, and treated with 12-week EBR/GZR were enrolled from 10 hospitals in Taiwan between August 2017 and December 2018. All clinical and virologic data were collected at each participating center. Primary efficacy endpoint was sustained virologic response at week 12 (SVR12) after end of the EBR/GZR therapy, assessed in the per-protocol population, which excluded patients with important deviations from the protocol. Analysis was also performed based on the modified full analysis set, which included all allocated patients receiving at least 4-week medication. Virologic failure was recorded as breakthrough, nonresponse, or relapse. Safety was assessed through collection of adverse events, physical examination, vital signs, and standard laboratory evaluations.ResultsPer protocol SVR12 rates were 99.5% (1169/1175) for all HCV genotype 1 patients. Among patients with stage 4 or 5 chronic kidney diseases, 100% (107/107) achieved SVR12. In univariate analyses, variables associated with SVR12 were treatment termination (P < 0.0001) and treatment adherence (P < 0.0001) in the mFAS population. Overall, 22.3% of the patients experienced adverse events during treatment. Seven patients did not complete the treatment, five due to liver-unrelated deaths, one due to adverse event and one due to epilepsy.ConclusionsEBR/GZR treatment was highly effective and well tolerated.